ClinicalTrials.gov
public full text
Public Domain
Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
The purpose of this study is to test feasibility of measuring flumazenil-induced changes in cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of hepatic encephalopathy (HE) in subjects with non-alcoholic liver cirrhosis. This study is a double-blind, placebo-controlled, randomized, cross-over design.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Acetyl-L-Carnitine In Severe Hepatic Encephalopathy#915358
- Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124#827144
- MRSI Evaluation for Minor Stroke With Large Vessel Occlusion#1164545
- The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research#4506
- Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement#881273
Record · ID 1419987
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive